Patient presents with signs and symptoms suggestive of neuroendocrine carcinoma (NEC).  Clinical presentation includes [specific symptoms e.g., flushing, diarrhea, wheezing, abdominal pain, weight loss, fatigue]  Onset of symptoms reported as [onset timeframe e.g., gradual over several months, acute onset].  Physical examination reveals [relevant findings e.g., palpable abdominal mass, hepatomegaly, lymphadenopathy].  Differential diagnosis includes carcinoid syndrome, pancreatic neuroendocrine tumor (PNET), small cell lung cancer (SCLC), and other neuroendocrine neoplasms (NENs).  Laboratory investigations include [tests ordered e.g., chromogranin A (CgA), 5-HIAA urine test, serum serotonin, complete blood count (CBC), comprehensive metabolic panel (CMP)]. Imaging studies such as [imaging modalities e.g., CT scan of the abdomen and pelvis, octreotide scan, endoscopic ultrasound (EUS)] will be performed to assess for primary tumor location and metastatic disease.  Biopsy is planned to confirm the diagnosis of neuroendocrine carcinoma and determine tumor grade and differentiation.  Preliminary staging based on available clinical information suggests [stage if applicable, otherwise state 'staging pending further investigation'].  Treatment plan will be determined following histopathological confirmation and staging, and may include surgical resection, chemotherapy, targeted therapy (e.g., everolimus, sunitinib), somatostatin analogs (e.g., octreotide, lanreotide), peptide receptor radionuclide therapy (PRRT), and supportive care.  Patient education provided regarding neuroendocrine tumor diagnosis, prognosis, treatment options, and potential side effects.  Follow-up scheduled for [follow-up timeframe] to review pathology results and discuss definitive treatment strategy. Referral to oncology and other specialists as indicated.  ICD-10 code C7A.1 (malignant neuroendocrine tumor of unspecified site) is provisionally assigned pending definitive diagnosis and primary site confirmation.